Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- EVLO
- Price
- -
- Stock movement up
- +- (0.00%)
- Company name
- Evelo Biosciences Inc
- Exchange
- (PINK ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 7.59K
- Ent value
- 30.08M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -98.86%
- 3 year return (CAGR)
- -98.64%
- 5 year return (CAGR)
- -91.47%
- 10 year return (CAGR)
- -
Last updated: 2024-12-17
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
EVLO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 18.98M |
| EPS (TTM) | -4.74 |
| FCF per share (TTM) | -7.47 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -2.41M |
| Operating income (TTM) | -76.74M |
| Net income (TTM) | -82.35M |
| EPS (TTM) | -4.74 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 17.26M |
| Net receivables | 0.00 |
| Total current assets | 18.94M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 2.98M |
| Total assets | 20.63M |
| Accounts payable | 526.00K |
| Short/Current long term debt | 33.95M |
| Total current liabilities | 39.76M |
| Total liabilities | 47.33M |
| Shareholder's equity | -26.71M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -73.70M |
| Capital expenditures (TTM) | 287.00K |
| Free cash flow (TTM) | -129.83M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -399.23% |
| Return on Invested Capital | -1137.26% |
| Cash Return on Invested Capital | -1793.00% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
No data
Stock price data
| Open | 0.00 |
| Daily high | 0.00 |
| Daily low | 0.00 |
| Daily Volume | 2K |
| 1y analyst estimate | 10.00 |
| Beta | 1.30 |
| EPS (TTM) | -4.74 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| EVLO | S&P500 | |
| Current price drop from All-time high | -100.00% | -0.59% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 14 Oct 2024 | 9 Mar 2009 |
| Avg drop from high | -69.29% | -10.84% |
| Avg time to new high | 416 days | 12 days |
| Max time to new high | 978 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
7.59K
Marketcap category
Small-cap
Description
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Employees
66
Website
Investor relations
-
SEC filings
CEO
Balkrishan Gill
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page